Position
Siren, L.L.C. in Neumora Therapeutics, Inc.
Back to the book · All holders of NMRA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $1.01M$1.79 → $1.95
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 6.29M | $11.3M | — | — | — | 0.3% |
| Q1 2026 | 8.5M | $16.6M | $1.95 | $1.01M | $4.31M | 0.5% |